Full-Time

Principal Systems Engineer

Updated on 9/4/2026

Solventum

Solventum

10,001+ employees

Global healthcare company: wound care, dental

Compensation Overview

$124k - $170.5k/yr

+ Variable incentive pay

No H1B Sponsorship

Canada + 1 more

More locations: San Antonio, TX, USA

Hybrid

Requires travel to San Antonio, Texas at least three days per week. Relocation assistance may be authorized.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
GMP
Quality Assurance (QA)
Cybersecurity
Risk Management
C/C++

Get referred to Solventum

See people who can refer or advise you

Requirements
  • A Bachelor's degree or higher in engineering from an accredited institution and a minimum of seven years of combined industry experience in systems engineering and/or product design in a regulated environment, or a high school diploma/GED and eleven years of combined industry experience in systems engineering and/or product design in a regulated environment.
  • Demonstrated understanding and experience in the design, development, and testing of embedded, electro-mechanical medical devices.
  • Experience in a regulated design environment with medical device development and FDA- or ISO-registered work experience.
  • Experience with GMP-certified manufacturing processes and UL/IEC standards.
  • Hands-on systems engineering experience with working knowledge of C or C++ embedded systems, IoT communication, and cybersecurity risk management.
  • Experience leading system requirements, architecture, integration, and testing through formal design reviews to final verification and validation.
  • Experience facilitating technical working sessions and engineering reviews.
  • Proven experience identifying, quantifying, and mitigating technical risks.
  • Strong self-directed execution, problem-solving, and critical-thinking skills.
  • Legal authorization to work in the country of employment without sponsorship for employment visa status.
Responsibilities
  • Elicit, document, and manage system-level requirements, ensuring full traceability from user needs to low-level components.
  • Define system boundaries, interfaces, and data flows between subsystems, including embedded software, sensors, and mechanical assemblies.
  • Participate in ISO 14971 risk-management activities, including hazard analysis, Design Failure Mode and Effects Analysis, and usability activities.
  • Work with the verification and validation team to execute comprehensive verification and validation strategies demonstrating that the system meets all design inputs and intended uses.
  • Act as the technical bridge between mechanical, electrical, software, and quality teams to resolve design conflicts.
  • Author and review technical files for global regulatory submissions, including FDA 510(k), Premarket Approval, and European Union Medical Device Regulation submissions.
  • Provide leadership and direction to the technical team through requirements definition, design, implementation, and validation to achieve coherent and efficient system architecture.
  • Maintain operational knowledge of the organization's technologies, products, customers, and customer needs.
  • Perform technical planning, system design and architecture, and evaluation of alternatives including cost, risk, and total-system supportability.
  • Develop in-depth knowledge of product development, manufacturing, engineering, financial, legal, sales, and marketing functions and interfaces as required.
  • Manage product documentation through established processes.
  • Participate in reasonable work activities deemed suitable and assigned by management.
  • Conform to, support, and enforce company policies and procedures.
Desired Qualifications
  • Experience with IEC 60601-1.
  • Experience with graphical user interface development.
  • Experience with wireless communications, including cellular, Bluetooth, and Wi-Fi, and/or location services such as GPS.
  • Experience driving continuous improvement of processes, tooling, and technical deliverables.

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Maplewood, Minnesota

Founded

2023

Get referred to Solventum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic sales rose 9.5%, and management lifted EPS guidance to $7.10-$7.20.
  • Dental grew 15.2% organically in Q2 2026, showing pricing and product momentum.
  • Solventum exited nearly 70% of TSAs and targets 90% by end-2026.

What critics are saying

  • ERP advance orders inflated Q2 by about $125 million, and Q3 reverses.
  • HIS now faces separation, and AI-native competitors threaten revenue-cycle workflows by 2027.
  • Thermo Fisher's $4.1 billion filtration acquisition removes Solventum's fastest-growing cash engine.

What makes Solventum unique

  • Solventum controls 3M-origin IP, with 7,300 patents across MedSurg, dental, and filtration.
  • Its $200 million Eagan Innovation Hub centralizes wound care, sterilization, and digital health R&D.
  • Management expects nearly 20 launches through Q1 2028, anchoring category depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

8%
Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 11th, 2026
Solventum beats Q2 estimates with $2.21B revenue, raises EPS guidance 10% amid HIS separation

Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.

Yahoo Finance
Aug 9th, 2026
Solventum raises 2026 outlook with 9.5% Q2 growth boosted by $125M advanced orders and $100M tariff refund

Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.

PR Newswire
Aug 5th, 2026
Solventum Q2 sales up 9.5%, raises 2026 guidance and plans to separate Health Information Systems unit

Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.

Yahoo Finance
Aug 2nd, 2026
Solventum appoints Neil Zieselman as chief accounting officer

Solventum has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed Mary Wilcox, who is retiring. Zieselman brings experience from Surgery Partners, Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya. He is a licensed CPA. The company's stock trades at $85.44. It has delivered a 9.5% return over the past week and 19.1% over the past year. For investors, Zieselman's background in healthcare and corporate finance may influence Solventum's financial controls, reporting quality, and regulatory engagement. His approach could shape disclosure practices and capital allocation commentary in future earnings calls. Interest payments are not well covered by earnings, making any changes under the new Chief Accounting Officer particularly important for risk assessment.